You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

ADLARITY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Adlarity patents expire, and what generic alternatives are available?

Adlarity is a drug marketed by Corium and is included in one NDA. There are nine patents protecting this drug.

This drug has eighty-nine patent family members in eleven countries.

The generic ingredient in ADLARITY is donepezil hydrochloride. There are thirty-two drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the donepezil hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Adlarity

A generic version of ADLARITY was approved as donepezil hydrochloride by AUROBINDO on May 31st, 2011.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ADLARITY?
  • What are the global sales for ADLARITY?
  • What is Average Wholesale Price for ADLARITY?
Summary for ADLARITY
International Patents:89
US Patents:9
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 160
Patent Applications: 4,015
Drug Prices: Drug price information for ADLARITY
What excipients (inactive ingredients) are in ADLARITY?ADLARITY excipients list
DailyMed Link:ADLARITY at DailyMed
Drug patent expirations by year for ADLARITY
Drug Prices for ADLARITY

See drug prices for ADLARITY

Pharmacology for ADLARITY

US Patents and Regulatory Information for ADLARITY

ADLARITY is protected by nine US patents and one FDA Regulatory Exclusivity.

Patents protecting ADLARITY

Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

Donepezil transdermal delivery system
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Donepezil transdermal delivery system
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Systems and methods for long term transdermal administration
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

Systems comprising a composite backing and methods for long term transdermal administration
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

Methods for treating alzheimer's disease with donepezil transdermal system
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

Donepezil transdermal delivery system
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting ADLARITY

NEW PRODUCT
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Corium ADLARITY donepezil hydrochloride SYSTEM;TRANSDERMAL 212304-001 Mar 11, 2022 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Corium ADLARITY donepezil hydrochloride SYSTEM;TRANSDERMAL 212304-002 Mar 11, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Corium ADLARITY donepezil hydrochloride SYSTEM;TRANSDERMAL 212304-001 Mar 11, 2022 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Corium ADLARITY donepezil hydrochloride SYSTEM;TRANSDERMAL 212304-001 Mar 11, 2022 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Corium ADLARITY donepezil hydrochloride SYSTEM;TRANSDERMAL 212304-002 Mar 11, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ADLARITY

See the table below for patents covering ADLARITY around the world.

Country Patent Number Title Estimated Expiration
Japan 2022087276 メマンチン経皮送達システム ⤷  Sign Up
Mexico 2018008190 SISTEMAS Y METODOS PARA LA ADMINISTRACION TRANSDERMICA A LARGO PLAZO. (SYSTEMS AND METHODS FOR LONG TERM TRANSDERMAL ADMINISTRATION.) ⤷  Sign Up
South Korea 20190034601 염 약물의 염 약물에서 중성 약물으로의 제자리 전환에 의한 저용해도 또는 불안정한 이온화되지 않은 중성 약물의 경피성 제제 및 전달 방법 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2018022818 ⤷  Sign Up
South Korea 102406528 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ADLARITY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0296560 SPC/GB97/023 United Kingdom ⤷  Sign Up PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
0296560 2/1998 Austria ⤷  Sign Up PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.